The Continued Need for Transparent Evidence on the Cost Effectiveness of Drugs for Rare Diseases

Pharmacoeconomics. 2021 Apr;39(4):479-480. doi: 10.1007/s40273-021-01007-8. Epub 2021 Mar 6.

Authors

Jesse Elliott¹, George A Wells^{2

3}, Doug Coyle²

Affiliations

¹ School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, K1G 5Z3, Canada. jcrai065@uottawa.ca.
² School of Epidemiology and Public Health, University of Ottawa, 600 Peter Morand Crescent, Ottawa, ON, K1G 5Z3, Canada.
³ University of Ottawa Heart Institute, Ottawa, ON, Canada.

PMID: 33674998
DOI: 10.1007/s40273-021-01007-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Cannabidiol*
Cost-Benefit Analysis
Humans
Lennox Gastaut Syndrome*
Pharmaceutical Preparations*
Rare Diseases / drug therapy
Seizures

Substances

Pharmaceutical Preparations
Cannabidiol